GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs standard-of-care rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This retrospective analysis of GOYA aimed to assess the association between progression-free survival (PFS) and overall survival (OS) with positron emission tomography (PET)-based complete response (CR) status. Overall, 1418 patients were randomly assigned to receive 8 21-day cycles of obinutuzumab (n = 706) or rituximab (n = 712) plus 6 or 8 cycles of CHOP. Patients received a mandatory fluoro-2-deoxy-D-glucose-PET/computed tomography scan at baseline and end of treatment. After a median follow-up of 29 months, the numbers of independent review committee-assessed PFS and OS events in the entire cohort were 416 (29.3%) and 252 (17.8%), respectively. End-of-treatment PET CR was highly prognostic for PFS and OS according to Lugano 2014 criteria (PFS: hazard ratio [HR], 0.26; 95% confidence interval [CI], 0.19-0.38; P < .0001; OS: HR, 0.12; 95% CI, 0.08-0.17; P < .0001), irrespective of international prognostic index score and cell of origin. In conclusion, the results from this prospectively acquired large cohort corroborated previously published data from smaller sample sizes showing that end-of-treatment PET CR is an independent predictor of PFS and OS and a promising prognostic marker in DLBCL. Long-term survival analysis confirmed the robustness of these data over time. Additional meta-analyses including other prospective studies are necessary to support the substitution of PET CR for PFS as an effective and practical surrogate end point.

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA / Kostakoglu, Lale; Martelli, Maurizio; Sehn, Laurie H; Belada, David; Carella, Angelo-Michele; Chua, Neil; Gonzalez-Barca, Eva; Hong, Xiaonan; Pinto, Antonio; Shi, Yuankai; Tatsumi, Yoichi; Knapp, Andrea; Mattiello, Federico; Nielsen, Tina; Sahin, Deniz; Sellam, Gila; Oestergaard, Mikkel Z; Vitolo, Umberto; Trněný, Marek. - In: BLOOD ADVANCES. - ISSN 2473-9529. - 5:5(2021), pp. 1283-1290. [10.1182/bloodadvances.2020002690]

End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA

Martelli, Maurizio;
2021

Abstract

GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs standard-of-care rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This retrospective analysis of GOYA aimed to assess the association between progression-free survival (PFS) and overall survival (OS) with positron emission tomography (PET)-based complete response (CR) status. Overall, 1418 patients were randomly assigned to receive 8 21-day cycles of obinutuzumab (n = 706) or rituximab (n = 712) plus 6 or 8 cycles of CHOP. Patients received a mandatory fluoro-2-deoxy-D-glucose-PET/computed tomography scan at baseline and end of treatment. After a median follow-up of 29 months, the numbers of independent review committee-assessed PFS and OS events in the entire cohort were 416 (29.3%) and 252 (17.8%), respectively. End-of-treatment PET CR was highly prognostic for PFS and OS according to Lugano 2014 criteria (PFS: hazard ratio [HR], 0.26; 95% confidence interval [CI], 0.19-0.38; P < .0001; OS: HR, 0.12; 95% CI, 0.08-0.17; P < .0001), irrespective of international prognostic index score and cell of origin. In conclusion, the results from this prospectively acquired large cohort corroborated previously published data from smaller sample sizes showing that end-of-treatment PET CR is an independent predictor of PFS and OS and a promising prognostic marker in DLBCL. Long-term survival analysis confirmed the robustness of these data over time. Additional meta-analyses including other prospective studies are necessary to support the substitution of PET CR for PFS as an effective and practical surrogate end point.
2021
cyclophosphamide; doxorubicin; fluorodeoxyglucose f 18; obinutuzumab; prednisone; rituximab; tumor marker; vincristine
01 Pubblicazione su rivista::01a Articolo in rivista
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA / Kostakoglu, Lale; Martelli, Maurizio; Sehn, Laurie H; Belada, David; Carella, Angelo-Michele; Chua, Neil; Gonzalez-Barca, Eva; Hong, Xiaonan; Pinto, Antonio; Shi, Yuankai; Tatsumi, Yoichi; Knapp, Andrea; Mattiello, Federico; Nielsen, Tina; Sahin, Deniz; Sellam, Gila; Oestergaard, Mikkel Z; Vitolo, Umberto; Trněný, Marek. - In: BLOOD ADVANCES. - ISSN 2473-9529. - 5:5(2021), pp. 1283-1290. [10.1182/bloodadvances.2020002690]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1689354
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 32
social impact